Abstracts by key term: Savings
With the Pharmaceutical Market Reorganization Act (AMNOG) in 2011, the German legislature enshrined the principle of benefit-based pricing in law. Since then, price negotiations have been largely based on the additional benefits of a medicine, in addition to the annual therapy costs of comparable medicines and retail prices in other EU countries. The aim of the law was to negotiate the price for new drugs with patent protection or new document protection following an additional benefit assessment. The benefit assessment is carried out compared to the appropriate comparator therapy (zVT). This determined additional benefit, together with the previously mentioned criteria, forms the basis for the reimbursement price negotiation, which is carried out between the pharmaceutical company and the umbrella association of health insurance companies (GKV-SV) on the basis of the resolution of the Federal Joint Committee (G-BA). The resulting price discount on the introductory price is the basis for calculating the AMNOG savings in accordance with Section 130b SGB V. These are calculated using the sales difference between the real sales considered (price corresponding to reimbursement amount negotiation x quantity) and a “fictitious” sales (price without Reimbursement amount negotiation x quantity) which would have been reimbursed without the AMNOG price negotiations.